Adenovirus-mediated transfer of RA538 gene and its antitumor effect

The RA538 cDNA was transferred into human ovarian cancer cell line SK-OV-3 and human melanoma cell line WM-983A by its recombinant adenoviral vector constructed through homologous recombination. It was demonstrated that the recombinant adenovirus could transfer RA538 gene with high efficiency, and could obviously inhibit tumor growth, with the inhibiting rates of 85% and 73% respectively, at the same time greatly repress the colony forming ability of the cells. The therapeutic experiments on transplanted subcutaneous tumor model in nude mice demonstrated that RA538 could significantly inhibit tumor growth. Flow cytometry and DNA fragmentation analysis indicated that RA538 could induce the cell cycle G1 arrest/apoptosis of the tumor cells. The expression of cmyc gene was found pronouncedly reduced by Western blot analysis. These results suggest that the RA538 recombinant adenovirus could be a promising drug in cancer gene therapy.     

腺病毒介导RA538基因转移及其肿瘤抑制作用

采用同源重组方法构建RA5 3 8cDNA重组体腺病毒 ,通过转导人卵巢癌细胞系SK OV 3和人黑色素瘤细胞系WM 983A ,证实腺病毒可高效转导RA5 3 8基因 ,能显著抑制肿瘤细胞的生长 ,其抑制率分别达 85 %和 73 % ;并显著降低两细胞系的集落形成能力 .对两细胞系的裸鼠皮下移植瘤进行治疗实验结果表明 ,RA5 3 8能明显抑制肿瘤的生长 .流式细胞计数和DNA片段化分析证实 ,RA5 3 8可引起肿瘤细胞G1期阻滞和 /或凋亡 .对c myc蛋白的Westernblot分析发现 ,RA5 3 8有明显下调c myc基因表达的作用 .根据这些结果 ,我们认为RA5 3 8重组体腺病毒有可能成为有应用价值的肿瘤基因治疗药物 .